MX2022002198A - Composiciones y métodos para modular el empalme y la expresión de proteínas. - Google Patents
Composiciones y métodos para modular el empalme y la expresión de proteínas.Info
- Publication number
- MX2022002198A MX2022002198A MX2022002198A MX2022002198A MX2022002198A MX 2022002198 A MX2022002198 A MX 2022002198A MX 2022002198 A MX2022002198 A MX 2022002198A MX 2022002198 A MX2022002198 A MX 2022002198A MX 2022002198 A MX2022002198 A MX 2022002198A
- Authority
- MX
- Mexico
- Prior art keywords
- protein expression
- methods
- compositions
- alternative splicing
- splicing events
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Los eventos de empalme alternativo pueden dar lugar a transcritos de ARNm no productivos que, a su vez, pueden conducir a la expresión aberrante de proteínas, y los agentes terapéuticos que pueden dirigirse a los eventos de empalme alternativo en los genes pueden modular el nivel de expresión de proteínas funcionales en pacientes enfermos y/o inhibir la expresión aberrante de proteínas. En el presente documento se describen agentes terapéuticos y métodos que pueden usarse para tratar una afección provocada por estos eventos de empalme alternativo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962888887P | 2019-08-19 | 2019-08-19 | |
US202063049262P | 2020-07-08 | 2020-07-08 | |
PCT/US2020/047081 WO2021034985A1 (en) | 2019-08-19 | 2020-08-19 | Compositions and methods for modulating splicing and protein expression |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002198A true MX2022002198A (es) | 2022-05-24 |
Family
ID=74659533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002198A MX2022002198A (es) | 2019-08-19 | 2020-08-19 | Composiciones y métodos para modular el empalme y la expresión de proteínas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220290142A1 (es) |
EP (1) | EP4017979A4 (es) |
JP (1) | JP2022544702A (es) |
KR (1) | KR20220104677A (es) |
CN (1) | CN114746550A (es) |
AU (1) | AU2020334067A1 (es) |
BR (1) | BR112022002905A2 (es) |
CA (1) | CA3147970A1 (es) |
IL (1) | IL290595A (es) |
MX (1) | MX2022002198A (es) |
WO (1) | WO2021034985A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3976789A4 (en) * | 2019-05-27 | 2023-08-09 | Vision Pharma Pty Ltd | NEW TREATMENT FOR RETINITIS PIGMENTOSA |
JP2023526060A (ja) * | 2020-05-11 | 2023-06-20 | ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス | Syngap1中の機能喪失変異に関連する障害を処置するための組成物及び方法 |
WO2022271699A2 (en) * | 2021-06-21 | 2022-12-29 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
EP4373845A2 (en) * | 2021-07-23 | 2024-05-29 | The Children's Medical Center Corporation | Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use |
US20230265436A1 (en) * | 2022-02-24 | 2023-08-24 | Q-State Biosciences, Inc. | Therapeutics for syngap haploinsufficiency |
WO2023196841A2 (en) * | 2022-04-05 | 2023-10-12 | The Johns Hopkins University | Methods and materials for treating syngap1-associated neurodevelopmental disorders |
WO2023212625A1 (en) * | 2022-04-28 | 2023-11-02 | AcuraStem Incorporated | Syf2 antisense oligonucleotides |
WO2023220727A1 (en) * | 2022-05-13 | 2023-11-16 | The Trustees Of The University Of Pennsylvania | Compositions for treating syngap-1 related neurodevelopmental disorders |
WO2024005715A1 (en) * | 2022-06-28 | 2024-01-04 | Agency For Science, Technology And Research | Oligonucleotides |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009064920A2 (en) * | 2007-11-13 | 2009-05-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
CA2735129C (en) * | 2008-11-07 | 2012-06-26 | Centre Hospitalier Universitaire Sainte-Justine | Syngap1 dysfunctions and uses thereof in diagnostic and therapeutic applications for mental retardation |
JP6867945B2 (ja) * | 2014-10-03 | 2021-05-12 | コールド スプリング ハーバー ラボラトリー | 核内遺伝子出力の標的とされた増強 |
WO2017060731A1 (en) * | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
WO2017106211A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of polycystic kidney disease |
JP7049247B2 (ja) * | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | 腎臓病の処置のための組成物と方法 |
EP3933041B1 (en) * | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
EP3390635A4 (en) * | 2015-12-14 | 2019-05-01 | Cold Spring Harbor Laboratory | Antisense oligomers for the treatment of a tuberous sclerosis complex |
JP2019500345A (ja) * | 2015-12-14 | 2019-01-10 | コールド スプリング ハーバー ラボラトリー | 肝臓病の処置のための組成物および方法 |
CA3005128A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of eye diseases |
MX2019005588A (es) * | 2016-11-28 | 2019-10-15 | Ptc Therapeutics Inc | Metodos para modular corte y empalme de arn. |
PL3673080T3 (pl) * | 2017-08-25 | 2024-03-11 | Stoke Therapeutics, Inc. | Oligomery antysensowne do leczenia stanów i chorób |
KR20200070367A (ko) * | 2017-10-23 | 2020-06-17 | 스톡 테라퓨틱스, 인크. | 넌센스 매개 rna 분해 기반 병태 및 질환 치료를 위한 안티센스 올리고머 |
-
2020
- 2020-08-19 EP EP20855637.3A patent/EP4017979A4/en active Pending
- 2020-08-19 WO PCT/US2020/047081 patent/WO2021034985A1/en unknown
- 2020-08-19 KR KR1020227008965A patent/KR20220104677A/ko unknown
- 2020-08-19 CN CN202080073358.0A patent/CN114746550A/zh active Pending
- 2020-08-19 MX MX2022002198A patent/MX2022002198A/es unknown
- 2020-08-19 JP JP2022511203A patent/JP2022544702A/ja active Pending
- 2020-08-19 AU AU2020334067A patent/AU2020334067A1/en active Pending
- 2020-08-19 BR BR112022002905A patent/BR112022002905A2/pt unknown
- 2020-08-19 CA CA3147970A patent/CA3147970A1/en active Pending
-
2022
- 2022-02-13 IL IL290595A patent/IL290595A/en unknown
- 2022-02-16 US US17/673,226 patent/US20220290142A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114746550A (zh) | 2022-07-12 |
EP4017979A4 (en) | 2024-03-27 |
IL290595A (en) | 2022-04-01 |
US20220290142A1 (en) | 2022-09-15 |
WO2021034985A1 (en) | 2021-02-25 |
BR112022002905A2 (pt) | 2022-07-12 |
KR20220104677A (ko) | 2022-07-26 |
CA3147970A1 (en) | 2021-02-25 |
EP4017979A1 (en) | 2022-06-29 |
AU2020334067A1 (en) | 2022-03-17 |
JP2022544702A (ja) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002198A (es) | Composiciones y métodos para modular el empalme y la expresión de proteínas. | |
MX2020011786A (es) | Oligomeros antisentido para tratamiento de afecciones y enfermedades. | |
MX2021012989A (es) | Metodos y composiciones para modular el empalme y la traduccion. | |
CL2020002019A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
PH12020552060A1 (en) | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | |
MX2020003915A (es) | Proteinas trispecificas y metodos de uso. | |
SG10201808063PA (en) | Compositions for modulating ataxin 2 expression | |
EA201792214A1 (ru) | Соединения замещенного хиназолина | |
MX2018010676A (es) | Composiciones para modular la expresion de c9orf72. | |
EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
MX2022006858A (es) | Oligomeros antisentido para el tratamiento de condiciones y enfermedades. | |
MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
AU2018271862A1 (en) | Combination therapy | |
WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
WO2018125800A3 (en) | Metalloenzyme inhibitor compounds | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
CL2021002878A1 (es) | Tratamiento y prevención de enfermedades metabólicas | |
MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
WO2018125799A3 (en) | Metalloenzyme inhibitor compounds | |
MX2023009151A (es) | Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina. | |
WO2023086342A3 (en) | Opa1 antisense oligomers for treatment of conditions and diseases | |
MX2020005557A (es) | Agonistas de fxr para el tratamiento de enfermedades hepaticas. | |
MX2022005215A (es) | Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1). |